These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 16423537)

  • 1. Functional control of regulatory T cells and cancer immunotherapy.
    Wang RF
    Semin Cancer Biol; 2006 Apr; 16(2):106-14. PubMed ID: 16423537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells and Toll-like receptors in tumor immunity.
    Wang RF; Peng G; Wang HY
    Semin Immunol; 2006 Apr; 18(2):136-42. PubMed ID: 16469504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
    Wang RF
    Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T cells and cancer.
    Wang HY; Wang RF
    Curr Opin Immunol; 2007 Apr; 19(2):217-23. PubMed ID: 17306521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells and toll-like receptors in cancer therapy.
    Wang RF
    Cancer Res; 2006 May; 66(10):4987-90. PubMed ID: 16707417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells.
    Liu G; Zhao Y
    Immunology; 2007 Oct; 122(2):149-56. PubMed ID: 17848162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
    Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
    Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptors and immune regulation: implications for cancer therapy.
    Wang RF; Miyahara Y; Wang HY
    Oncogene; 2008 Jan; 27(2):181-9. PubMed ID: 18176599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer.
    Wang RF
    Semin Cancer Biol; 2006 Feb; 16(1):73-9. PubMed ID: 16140545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.
    Peng G; Wang HY; Peng W; Kiniwa Y; Seo KH; Wang RF
    Immunity; 2007 Aug; 27(2):334-48. PubMed ID: 17656116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
    Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation.
    Montagnoli C; Perruccio K; Bozza S; Bonifazi P; Zelante T; De Luca A; Moretti S; D'Angelo C; Bistoni F; Martelli M; Aversa F; Velardi A; Romani L
    Blood Cells Mol Dis; 2008; 40(1):55-62. PubMed ID: 17827038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.
    Peng G; Guo Z; Kiniwa Y; Voo KS; Peng W; Fu T; Wang DY; Li Y; Wang HY; Wang RF
    Science; 2005 Aug; 309(5739):1380-4. PubMed ID: 16123302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-specific regulatory T-cell subsets in transplantation tolerance regulatory T-cell subset quality reduces the need for quantity.
    Koenen HJ; Joosten I
    Hum Immunol; 2006 Sep; 67(9):665-75. PubMed ID: 17002896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.
    Masteller EL; Tang Q; Bluestone JA
    Semin Immunol; 2006 Apr; 18(2):103-10. PubMed ID: 16458533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding and converting regulatory T cells: a horizon for immunotherapy.
    Khattar M; Chen W; Stepkowski SM
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):199-204. PubMed ID: 19479206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptors on regulatory T cells: expanding immune regulation.
    Sutmuller RP; Morgan ME; Netea MG; Grauer O; Adema GJ
    Trends Immunol; 2006 Aug; 27(8):387-93. PubMed ID: 16814607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells.
    Zheng J; Liu Y; Qin G; Chan PL; Mao H; Lam KT; Lewis DB; Lau YL; Tu W
    J Immunol; 2009 Sep; 183(6):3742-50. PubMed ID: 19684082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.